Kelyniam Global Reports 2025 Financial Results

Core Insights - Kelyniam Global reported an 85% improvement in net loss for the year ended December 31, 2025, indicating a strong recovery in the second half of the year despite a challenging start [1] - The company received FDA 510(k) clearance for its innovative Fusion™ cranial and craniofacial implants, which utilize a next-generation biomaterial [1] Financial Performance - Total revenue for 2025 was $3.053 million, an 8% decrease from $3.328 million in 2024, with a solid recovery noted in the latter half of the year [1] - Gross profit decreased to $2.387 million from $2.594 million in the previous year [1] - EBITDA was $(81,661), compared to $322,824 in 2024, while the net loss improved to $(138,555) from $(920,206) [1] - Operating loss was $(96,449), a decline from operating income of $277,037 in 2024 [1] Product Development - The Fusion™ implants are designed with Kelyniam's patented integrated fixation system and can be delivered within 24-48 hours [1] - The new biomaterial combines PEEK with biphasic calcium phosphate (BCP), enhancing mechanical strength, biocompatibility, and promoting better bone regrowth [1] Strategic Decisions - Kelyniam received unsolicited acquisition interest in late 2025 but rejected the offer, deeming it inadequate in reflecting the company's full value and long-term growth potential [1] - The company remains focused on evaluating opportunities that align with its long-term strategy and enhance shareholder value [1]